The current CHANCE-2 trial demonstrated that DAPT with aspirin and ticagrelor was superior to aspirin and clopidogrel in reducing the risk of subsequent stroke in Chinese patients with minor ischemic stroke or high-risk TIA who were carriers of CYP2C19 loss-of-function (Wang et al., 2021). This evidence concerns the gene CYP2C19 and stroke disorder.